➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Harvard Business School
Boehringer Ingelheim
Express Scripts
Merck
Moodys
McKesson

Last Updated: June 24, 2021

DrugPatentWatch Database Preview

Drugs in Development Information for Obatoclax


Email this page to a colleague

« Back to Dashboard

What is the drug development status for Obatoclax?

Obatoclax is an investigational drug.

There have been 19 clinical trials for Obatoclax. The most recent clinical trial was a Phase 2 trial, which was initiated on August 1st 2012.

The most common disease conditions in clinical trials are Lymphoma, Leukemia, Lymphocytic, Chronic, B-Cell, and Lung Neoplasms. The leading clinical trial sponsors are Gemin X, National Cancer Institute (NCI), and Cephalon.

There are four hundred and seventy-eight US patents protecting this investigational drug and four international patents.

Recent Clinical Trials for Obatoclax
TitleSponsorPhase
Efficacy and Safety of Obatoclax Mesylate in Combination With Carboplatin and Etoposide Compared With Carboplatin and Etoposide Alone in Chemotherapy-Naive Patients With Extensive-Stage Small Cell Lung CancerCephalonPhase 3
Obatoclax Mesylate, Rituximab, and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Non-Hodgkin LymphomaNational Cancer Institute (NCI)Phase 1/Phase 2
Obatoclax for Systemic MastocytosisGemin XPhase 2

See all Obatoclax clinical trials

Clinical Trial Summary for Obatoclax

Top disease conditions for Obatoclax
Top clinical trial sponsors for Obatoclax

See all Obatoclax clinical trials

US Patents for Obatoclax

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Obatoclax   Try Before You Buy Pyrazol-3-ones that activate pro-apoptotic BAX Dana-Farber Cancer Institute, Inc. (Boston, MA)   Try Before You Buy
Obatoclax   Try Before You Buy Small molecules for the modulation of MCL-1 and methods of modulating cell death, cell division, cell differentiation and methods of treating disorders Dana-Farber Cancer Institute, Inc. (Boston, MA)   Try Before You Buy
Obatoclax   Try Before You Buy Methods for sensitizing a quiescent cancer stem cell to a BCR-ABL inhibitor The Regents of the University of California (Oakland, CA)   Try Before You Buy
Obatoclax   Try Before You Buy Precise delivery of therapeutic agents to cell mitochondria for anti-cancer therapy University of Georgia Research Foundation Inc. (Athens, GA)   Try Before You Buy
Obatoclax   Try Before You Buy Formulations for tailored drug release South Dakota Board of Regents (Pierre, SD) Sanford Health (Sioux Falls, SD)   Try Before You Buy
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Obatoclax

Drugname Country Document Number Estimated Expiration Related US Patent
Obatoclax Australia AU2012322660 2031-10-11   Try Before You Buy
Obatoclax Australia AU2017228527 2031-10-11   Try Before You Buy
Obatoclax Canada CA2851788 2031-10-11   Try Before You Buy
Obatoclax European Patent Office EP2766355 2031-10-11   Try Before You Buy
Obatoclax World Intellectual Property Organization (WIPO) WO2013055949 2031-10-11   Try Before You Buy
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Colorcon
AstraZeneca
Express Scripts
Merck
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.